Objective-To study the effect of transdermal scopolamine on heart rate variability, baroreflex sensitivity, and exercise performance in patients with heart failure and age matched healthy volunteers. Design-Double blind, randomised, placebo controlled, crossover study. Patients-16 patients with chronic, stable heart failure due to ischaemic cardiomyopathy (mean (SEM) age 58 (2) Results-In both groups scopolamine produced a reduction in the 24 h average heart rate and an increase in the time domain measures of heart rate variability. Both the incidence and severity of ventricular arrhythmias remained unchanged. Baroreflex sensitivity, evaluated by the phenylephrine technique, increased significantly (P < 0.001) with scopolamine in patients with heart failure (6.22 (2-81) mslnun Hg) and in healthy volunteers (5.97 (2*20) mslnun Hg) as did the amplitude of respiratory sinus arrhythmia, computed by autoregressive spectral analysis of 10 min electrocardiographic recordings (319.9 (123.5) and 657-3 (126-6) ms' respectively, P < 0.001). While exercise performance did not change, heart rate at submaximal exercise was significantly reduced by scopolamine in each group. Conclusions-In patients with mild to moderate heart failure low doses of scopolamine increased tonic and reflex cardiac vagal activity. This was achieved without affecting exercise tolerance or the incidence and severity of ventricular arrhythmias. (Heart 1996;75:274-280) 
Abstract
Objective-To study the effect of transdermal scopolamine on heart rate variability, baroreflex sensitivity, and exercise performance in patients with heart failure and age matched healthy volunteers. Design-Double blind, randomised, placebo controlled, crossover study. Patients-16 patients with chronic, stable heart failure due to ischaemic cardiomyopathy (mean (SEM) age 58 (2) years; mean (SEM) radionuclide left ventricular ejection fraction 28 (2)%; New York Heart Association class II-III) and eight age matched healthy controls. Intervention-Transdermal scopolamine (500 4ug delivered over 72 h) or a placebo patch was administered for 48 h. Main outcome measures-Indices of tonic and reflex cardiac vagal activity and exercise performance. Results-In both groups scopolamine produced a reduction in the 24 h average heart rate and an increase in the time domain measures of heart rate variability. Both the incidence and severity of ventricular arrhythmias remained unchanged. Baroreflex sensitivity, evaluated by the phenylephrine technique, increased significantly (P < 0.001) with scopolamine in patients with heart failure (6.22 (2-81) mslnun Hg) and in healthy volunteers (5.97 (2*20) mslnun Hg) as did the amplitude of respiratory sinus arrhythmia, computed by autoregressive spectral analysis of 10 min electrocardiographic recordings (319.9 (123.5) and 657-3 (126-6) ms' respectively, P < 0.001). While exercise performance did not change, heart rate at submaximal exercise was significantly reduced by scopolamine in each group. Conclusions-In patients with mild to moderate heart failure low doses of scopolamine increased tonic and reflex cardiac vagal activity. This was achieved without affecting exercise tolerance or the incidence and severity of ventricular arrhythmias.
(Heart 1996;75:274-280) Keywords: scopolamine; chronic heart failure; RR interval variability; exercise performance Neurohumoral activation' and reduced cardiac vagal control23 are independent predictors of a poor prognosis in patients with ischaemic heart disease or chronic heart failure (CHF). Although in humans there is no direct proof of a causal relation between autonomic imbalance and mortality, interventions which can antagonise neurohumoral activation have been successful in improving the survival of patients with CHF or ischaemic heart disease, or both. 4 Increasing parasympathetic activity could provide an alternative means of correcting the autonomic imbalance in CHF. Studies in humans have shown that this can be achieved by the administration of very low doses of muscarinic blocking agents, such as atropine or scopolamine in patients after myocardial infarction.5-8 Although these alkaloids are normally used for their anticholinergic properties, at very low doses they can induce a paradoxical increase in cardiac vagal activity. This, in turn, could increase the electrical stability of the ventricular myocardium and protect against ischaemia induced ventricular fibrillation.9-" Several problems, however, might arise from the clinical use of small doses of muscarinic blocking agents. Firstly, it is not clear whether increasing vagal efferent activity would be effective in improving the autonomic balance to the heart in patients with CHF. Experimental studies have indicated that a reduction in the number and affinity of muscarinic receptors'2 and an impairment in their intracellular transduction mechanisms'3 (rather than a decrease in central vagal traffic) might be chiefly responsible for the reduced cardiac vagal tone in CHF. Secondly, vagal stimulation exerts a negative inotropic effect on the ventricular myocardium."4 Finally, it has been suggested that the vagally mediated reflex bradycardia which can accompany acute ischaemia could promote arrhythmias by unmasking ventricular automaticity.
II
The aims of the present study were to answer the following questions: (1) (2) years) with Low doses ofscopolamine in heartfailure stable mild to moderate CHF and eight age matched (mean (SEM) age 54 (4) years) healthy volunteers. The latter, who were recruited by advertisement, had a normal physical examination and were not taking any medication.
Participants with prostatism and/or a family history of glaucoma, diabetes mellitus, atrial fibrillation, cardiac conduction abnormalities, ischaemia limiting exercise, and liver and/or kidney diseases were excluded.
The active patch (Scopoderm TTS; CibaGeigy) contains 1-5 mg of scopolamine and delivers 500 ,ug at an approximately constant rate over 72 h.'6 Participants were familiarised with the procedures and performed at least three incremental exercise tests (see later) before entering the study. Measurements of baroreflex sensitivity, exercise performance, and short-term RR interval variability were taken on three occasions: at baseline (no treatment) and 24 h after the two treatments-that is, after a scopolamine or a placebo patch. Twenty four h Holter monitoring was started 24 h after the application of either patch. In order to avoid carry over effects, the two treatments were separated by at least 1 week.'6 All participants were informed of the common side effects of scopolamine'6 and were asked to report them at any time during the study. Baroreflex sensitivity was assessed by the phenylephrine method.24 Beat to beat blood pressure recordings were obtained from the finger (2300 Finapres BP Monitor; Ohmeda, Englewood, Colorado, USA). Four to six rapid intravenous injections of phenylephrine hydrochloride were given at about 3 min intervals. The initial dose (0-09 mg in healthy volunteers and 0-15 mg in patients with CHF) was adjusted to obtain an increase between 15 and 25 mm Hg in systolic blood pressure. The test was then repeated until at least three recordings were made with the optimum dose of phenylephrine. The sensitivity of the baroreflex, expressed in ms/mm Hg, was obtained from the average slope of at least three regression lines relating the RR interval to the preceding systolic blood pressure.
EXERCISE TESTING
Incremental upright cycle ergometry (Tunturi, Finland) was performed at the end of each visit. The starting work rate of 25 W was increased by 25 W every 5 min until exhaustion. Inspired air volume (Harvard Apparatus, Kent, UK), expired oxygen and carbon dioxide concentrations (Servomex 570A and Servomex PA404, Sussex), and a three lead ECG were recorded throughout the test. The gas analysers were calibrated before each test and all volumes were corrected to standard temperature and pressure (dry). Peak oxygen consumption (VO2) was taken from the mean over the last completed minute of exercise. Heart rate was calculated over the last minute of each work rate.
TWENTY FOUR H HOLTER MONITORING
Twenty four h ECG monitoring (modified VI and V5 leads) was performed using a two channel ECG recorder (Oxford MR14; Oxford Medical Instruments). The recordings were digitised at 128 samples/s and submitted to standard algorithms for QRS labelling and editing (Biomedical Systems, St Louis, Missouri, USA). They were then analysed for the frequency of premature ventricular complexes (h-') and the presence of ventricular repetitive arrhythmias (couplets and salvos of three or more ventricular extrasystoles). The standard deviation of all normal RR intervals (SDNN, ms) and of the mean RR intervals for all 5 min segments (SDANN index, ms) of a 24 h ECG recording, and the percentage of differences between adjacent normal RR intervals greater than 50 ms (pNN50, %) were automatically calculated. Each time domain measure was also computed for daytime and Casadei, Conway, Forfar, Sleight night time separately. Data from one patient were excluded because of the poor quality of the 24 h ECG recording.
All participants completed a questionnaire about their daytime activities, time to bed and wake up time. The conditions under which the two 24 h ECG recordings were performed, were, as far as possible, standardised for each participant.
STATISTICAL ANALYSIS
Data were examined for balanced allocation and absence of carry over effects according to the recommendation of Hills and Armitage"5 for crossover trials. The frequency distribution of each variable was plotted and assessed for skewness using the value of the standardised third moment around the mean. If the skewness coefficient was > 1, the data were log transformed and re-examined. This procedure led to a normal distribution in all cases. Repeated measures analysis of variance (SPSS for Windows, Release 6; SPSS, Chicago, Illinois, USA) was used to test for differences within the trial stages and between participant groups-that is, patients with CHF versus healthy volunteers. Interaction between participant groups and the effect of scopolamine were also assessed. Values are presented as mean (SEM). Significance was accepted at P < 0 05.
Short-term intraparticipant reproducibility of measures of spectral power, baroreflex sensitivity, and exercise performance was evaluated by computing the mean and standard deviation of the differences between measurements (taken during placebo and at baseline).25 The interclass correlation coefficient of the two measurements was also obtained. Table 1 shows the mean differences between the data collected in the placebo period and at baseline, their standard deviation and the correlation coefficient of the two measurements. There was no statistical difference between the placebo and baseline data. Precision was calculated according to the formula of Hills and Armitage25 and indicates the change with active treatment that this trial could detect with a statistical power of 09.
Results

REPRODUCIBILITY OF THE TESTS AND STATISTICAL POWER OF THE STUDY
Measurements of baroreflex sensitivity and peak VO2 showed satisfactory stability (table  1) . Spectral analysis data, however, were less reproducible with the exception of the absolute power of the HF component (a measurement of the amplitude of respiratory sinus arrhythmia).
BASELINE CHARACTERISTICS OF PATIENTS WITH CHRONIC HEART FAILURE
There were no significant differences between the baseline measurements in patients allocated to placebo or transdermal scopolamine. All patients had a documented myocardial infarction and had been in stable heart failure for at least 3 months. They were all taking diuretics and 13 of 16 had been receiving angiotensin converting enzyme inhibitors for a mean (SEM) of 14 (1) from 1 (y=5-8+1-01x, r=0-70, P< 0-001), indicating that scopolamine caused a proportional increase over the entire range of initial baroreflex sensitivity.
POWER SPECTRAL ANALYSIS OF RR INTERVAL VARIABILITY
Results of the spectral analysis were expressed in absolute and normalised units-that is, as a percentage of the spectral power calculated from 0-03 to 0-8 Hz. This allowed us to investigate the effects of scopolamine on the spectral power and its distribution across the frequency axis.
Supine
Scopolamine increased the mean RR interval, its variance, and the absolute power of the HF component ( fig 2) (fig 3) . This is consistent with impairment in the sensitivity of the baroreflex and abnormal cardiac sympathovagal balance in patients with CHF. 26 Interestingly, in these patients scopolamine tended to restore the physiological rise in the normalised power of LF (P = 0-11) on standing (fig 3) . Table 3 summarises the data from 24 CHF, chronic heart failure; HR, heart rate; bpm, beats/min; SDNN, standard de normal RR intervals; SDANN, standard deviation of the mean RR intervals for a ments of a 24 h ECG recording; pNN 50, percentage of differences between adj RR intervals greater than 50 ms.
TWENTY FOUR H HOLTER MONITORING
*P < 0-01 versus patients with CHF given placebo; tP < 0-001 for comparison bets and scopolamine in each of the two groups; tP < 0 05 versus patients with CHF lamine (the effect was greater in healthy volunteers than in patients with CHF).
dermal scopolamine during placel domain indices of 24 h RR interval in healthy volunteers were significan than in patients with CHF. Scopola duced a significant decrease in the r heart rate due to a reduction in da night time heart rate. Although tin indices of RR interval variability we cantly augmented by scopolamine groups, this effect was of greater ma healthy volunteers than in patients i ( Figure 4 Mean (SEM) heart rate (bpm, bea during incremental cycle ergometry in patients heart failure (circles) and in age matched heah volunteers (triangles) after placebo (open symb transdermal scopolamine (closed symbols). *P **P < 0005 for comparison of scopolamine v age matched healthy volunteers. ¶P < 0-05for ofscopolamine v placebo in patients with heart lamine. One patient receiving placebo felt light headed, while two volunteers receiving scopolamine complained of blurred vision.
Discussion
This study shows that transdermal scopolamine can reduce heart rate and increase 24 h RR interval variability, baroreflex sensitivity, and respiratory sinus arrhythmia in patients with mild to moderate CHF secondary to ischaemic heart disease. This was achieved without affecting exercise performance or the frequency and severity of ventricular arrhythmias.
MECHANISMS OF ACTION
The mechanism underlying the paradoxical vagomimetic effect of low doses of antimuscarinic drugs has not been fully explained. High doses of atropine have been shown to increase the firing of cardiac vagal efferent nerves through central stimulation of the vagal motomeurons.27 It is not clear, however, whether the same mechanism is responsible for the vagomimetic effect seen with plasma concentrations of scopolamine low enough to have a negligible peripheral antimuscarinic effect.
A preferential peripheral blockade of presynaptic muscarinic autoreceptors (M,) has been suggested as an alternative mechanism for the vagomimetic effects of low doses of antimuscarinic drugs. 28 The recent finding that the selective M,-muscarinic blocking agent, pirenzepine (which does not readily pass the bloodbrain barrier) has a vagomimetic effect similar to that of transdermal scopolamine29 supports this hypothesis. Low doses of scopolamine in heart failure that, in the presence of endothelial damage, the stimulation of muscarinic receptors induces coronary vasoconstriction.34 A recent report, however, has indicated that the paradoxical vagomimetic effect of a muscarinic blocking agent improves exercise tolerance in patients with ischaemia on effort.35 This might be the result of the reduction in heart rate at submaximal exercise seen with low doses of muscarinic blocking agents (fig 4) . Although vagal activity has a negative inotropic effect on the ventricular myocardium,'4 the vagomimetic effect of transdermal scopolamine was not accompanied by a deterioration in exercise performance in patients with CHF or healthy volunteers. Interestingly, in papillary muscles and isolated myocardiocytes the reduction in contractility induced by acetylcholine has been shown to last only for a few minutes.36 Thus, although the negative inotropic action of vagal activity could have a role in the context of short lasting reflex responses,37 it may not be sustained.
LIMITATIONS OF THE STUDY
The relation between RR interval variability and mortality in patients with heart failure has not been as extensively investigated as in postmyocardial infarction patients. Binder et al38 have shown that standard deviation of the 5 min mean RR interval in the 24 h ECG recording-that is, the SDANN index, was superior to left ventricular ejection fraction, pulmonary artery wedge pressure, cardiac index, and serum sodium levels in predicting the risk of death in patients with heart failure. The size of the trial was, however, rather small (n = 61) and the aetiology of heart failure was mainly dilated cardiomyopathy.
Our study was necessarily restricted to patients with mild to moderate CHF. Four patients with severe CHF, who were originally recruited, had to be excluded as a high incidence of arrhythmias (ventricular and supraventricular) prevented the assessment of baroreflex sensitivity and RR interval variability. Nevertheless, an increase in 24 h RR interval variability with transdermal scopolamine has been demonstrated in patients with advanced congestive heart failure awaiting cardiac transplantation.39 The number of patients who did not show a reduction in heart rate after transdermal scopolamine (seven of 21 patients) in this study was higher than in ours (3 of 15 patients), suggesting that the severity of the disease may affect the response to the drug. Although variability in the response to transdermal scopolamine has also been shown in healthy individuals,404' we found that the average increase in RR interval and its variability in patients with CHF was significantly smaller than in age matched healthy volunteers. This may be owing to a reduction in the number and affinity of muscarinic receptors in heart failure'2 13 or possibly to the concomitant treatment with angiotensin converting enzyme inhibitors as these agents have also been shown to increase cardiac vagal tone in patients with CHF.4' Interestingly, low doses of atropine have failed to elicit an increase in vagal tone in patients43 and animal models of CHF44 treated with digitalis, suggesting that cardiac glycosides and low doses of muscarinic blocking agents might exert a vagomimetic effect through similar mechanisms; thus the result of their simultaneous administration on cardiac vagal tone is not additive. A similar interaction between scopolamine and angiotensin converting enzyme inhibitors might have been responsible for the reduced vagomimetic effect of the former in patients with CHF.
Finally, we have no information regarding the safety and efficacy of long-term transdermal scopolamine. Severe adverse events have not been reported when the drug was administered for a longer period.45 This evidence, however, is based on trials of small size in healthy individuals. Whether the vagomimetic effect of transdermal scopolamine would be maintained on chronic treatment is still to be assessed.
